← Leaderboards
Michael A McVoy
Virginia Commonwealth University
$9,920,342
Attributed
$14,723,794
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,723,794 · 11
By mechanism
R01$12,875,678 · 5
R21$1,549,137 · 4
R03$298,979 · 2
Top collaborators
- Adam P. Geballe11 shared
- Mark R. Schleiss11 shared
- Laura Hertel4 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Prakash S. Nagarkatti$24,802,981
- Andrea B Staab$79,324
- Juan C Lacayo$75,229
- Bin Gao$700,617
- Gail E Christie$1,452,874
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusViralProteinsVaccinesCytomegalovirus InfectionsUnited StatesPreventInfectionAntibodiesCongenital AbnormalityBaseVirusResponseCytomegalovirus VaccinesComplexVaccine CandidateCellsAnimalsRecombinantsWomanAntibody FormationFibroblastsSubunit VaccinesPregnancy
Grant awards (37)
Modulation of cytomegalovirus replication by the viral temperance factor RL13$426,939
R21 · FY2025 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$623,296
R01 · FY2023 · HD
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$629,164
R01 · FY2022 · HD
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$635,993
R01 · FY2021 · HD
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$655,748
R01 · FY2020 · HD
Cytomegalovirus Tropisms for Oral Cells: Key to a Vaccine to Prevent Maternal Infection$486,723
R01 · FY2020 · AI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$689,044
R01 · FY2019 · HD
Cytomegalovirus tropisms for oral cells:key to a vaccine to prevent maternal infection$493,408
R01 · FY2019 · AI
Cytomegalovirus tropisms for oral cells:key to a vaccine to prevent maternal infection$493,101
R01 · FY2018 · AI
Cytomegalovirus tropisms for oral cells:key to a vaccine to prevent maternal infection$510,074
R01 · FY2017 · AI
Viral immunomodulation and rational CMV vaccine design$489,296
R01 · FY2015 · HD
Preclinical development of human CMV vaccines$771,327
R01 · FY2014 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$477,070
R01 · FY2014 · HD
Preclinical development of human CMV vaccines$775,296
R01 · FY2013 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$514,634
R01 · FY2013 · HD
An HBC-vectored peptide-based cytomegalovirus vaccine$74,750
R03 · FY2013 · AI · contact PI
Preclinical development of human CMV vaccines$827,143
R01 · FY2012 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$461,007
R01 · FY2012 · HD
An HBC-vectored peptide-based cytomegalovirus vaccine$74,750
R03 · FY2012 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$62,659
R01 · FY2012 · HD
Preclinical development of human CMV vaccines$26,071
R01 · FY2012 · AI · contact PI
Preclinical development of human CMV vaccines$773,901
R01 · FY2011 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$479,788
R01 · FY2011 · HD
Preclinical development of human CMV vaccines$760,622
R01 · FY2010 · AI · contact PI
Guinea pig cytomegalovirus as a model for vaccines that target endocytic entry$74,750
R03 · FY2010 · AI · contact PI
Ability of CMV Vaccines to Induce Antibodies that Block Endocytic Entry$182,133
R21 · FY2009 · AI · contact PI
Guinea pig cytomegalovirus as a model for vaccines that target endocytic entry$74,729
R03 · FY2009 · AI · contact PI
Ability of CMV Vaccines to Induce Antibodies that Block Endocytic Entry$206,604
R21 · FY2008 · AI · contact PI
Human cytomegalovirus alkaline nuclease (pUL98): potential antiviral target?$180,385
R21 · FY2008 · AI · contact PI
Human cytomegalovirus alkaline nuclease (pUL98): potential antiviral target?$205,576
R21 · FY2007 · AI · contact PI
HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING$250,600
R01 · FY2005 · AI
HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING$250,600
R01 · FY2004 · AI
Analysis of cytomegalovirus DNA cleavage/packaging genes$167,500
R21 · FY2004 · AI
HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING$250,600
R01 · FY2003 · AI
Analysis of cytomegalovirus DNA cleavage/packaging genes$180,000
R21 · FY2003 · AI
HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING$250,600
R01 · FY2002 · AI
HUMAN CYTOMEGALOVIRUS DNA CLEAVAGE AND PACKAGING$237,913
R01 · FY2001 · AI